205 related articles for article (PubMed ID: 30917164)
1. Adherence to immunomodulatory drugs in patients with multiple myeloma.
Cransac A; Aho S; Chretien ML; Giroud M; Caillot D; Boulin M
PLoS One; 2019; 14(3):e0214446. PubMed ID: 30917164
[TBL] [Abstract][Full Text] [Related]
2. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
3. Self-management of immunomodulatory drug treatment in multiple myeloma patients.
Cransac A; Aho S; Cosme E; Chretien ML; Favennec C; Schreder L; Boutet M; Gueneau P; Giroud M; Caillot D; Boulin M
Eur J Cancer Care (Engl); 2021 Jan; 30(1):e13356. PubMed ID: 33159353
[TBL] [Abstract][Full Text] [Related]
4. High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.
Feiten S; Chakupurakal G; Feustel HP; Maasberg M; Otremba B; Ehscheidt P; Hensel M; Hansen R; Weide R
Support Care Cancer; 2019 Nov; 27(11):4265-4271. PubMed ID: 30859307
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study.
Ononogbu O; Akindele O; Yazdanfard S; Fatima B; Abughosh S; Trivedi MV
Support Care Cancer; 2024 Jun; 32(7):407. PubMed ID: 38833106
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
8. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
[TBL] [Abstract][Full Text] [Related]
9. [Pomalidomide for multiple myeloma].
Dougé A; Lemal R; Chaleteix C
Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory drugs in multiple myeloma.
Andhavarapu S; Roy V
Expert Rev Hematol; 2013 Feb; 6(1):69-82. PubMed ID: 23373782
[TBL] [Abstract][Full Text] [Related]
11. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
13. Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis.
Silveira LP; Pádua CAM; Drummond PLM; Malta JS; Santos RMMD; Costa NL; Machado TRL; Hauck LM; Reis AMM
J Oncol Pharm Pract; 2022 Mar; 28(2):373-380. PubMed ID: 33583251
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
[TBL] [Abstract][Full Text] [Related]
15. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects.
Périchou J; Ranchon F; Herledan C; Huot L; Larbre V; Carpentier I; Lazareth A; Karlin L; Beny K; Vantard N; Schwiertz V; Caffin AG; Baudouin A; Sesques P; Brisou G; Ghesquières H; Salles G; Rioufol C
PLoS One; 2020; 15(12):e0243309. PubMed ID: 33275634
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
18. Oral therapy adherence and satisfaction in patients with multiple myeloma.
Solano M; Daguindau E; Faure C; Loriod P; Pain C; Maes AC; Marguet P; Kroemer M; Rumpler A; Fontan J; Deconinck E; Limat S; Clairet AL
Ann Hematol; 2021 Jul; 100(7):1803-1813. PubMed ID: 33938996
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
20. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
Mian H; Fiala M; Wildes TM
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):98-104.e1. PubMed ID: 31843543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
